tel-00827710, version 1 - 29 May 2013 <strong>de</strong>ndritic cell subs<strong>et</strong>s, and the generation of immunity to cellular antigens. Immunol Rev 199, 9-26. Heath, W.R., and Carbone, F.R. (2009). Dendritic cell subs<strong>et</strong>s in primary and secondary T cell responses at body surfaces. Nat Immunol 10, 1237-1244. Hemmer, B., Stefanova, I., Vergelli, M., Germain, R.N., and Martin, R. (1998). Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 160, 5807-5814. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-<strong>de</strong>pen<strong>de</strong>nt signaling pathway. Nat Immunol 3, 196-200. Hervas-Stubbs, S., Perez-Gracia, J.L., Rouzaut, A., Sanmamed, M.F., Le Bon, A., and Melero, I. (2011). Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17, 2619-2627. Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J., Yuh, L., Provost, N., and Frohlich, M.W. (2009). Integrated data from 2 randomized, double-blind, placebocontrolled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679. Hildner, K., E<strong>de</strong>lson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Cal<strong>de</strong>ron, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., <strong>et</strong> al. (2008). Batf3 <strong>de</strong>ficiency reveals a critical role for CD8alpha+ <strong>de</strong>ndritic cells in cytotoxic T cell immunity. Science 322, 1097-1100. Hodi, F.S., Butler, M., Oble, D.A., Sei<strong>de</strong>n, M.V., Haluska, F.G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, I., <strong>et</strong> al. (2008). Immunologic and clinical effects of antibody blocka<strong>de</strong> of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105, 3005-3010. Honda, K., Takaoka, A., and Taniguchi, T. (2006). Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349-360. Huber, J.P., and Farrar, J.D. (2011). Regulation of effector and memory T-cell functions by type I interferon. Immunology 132, 466-474. Huleatt, J.W., Jacobs, A.R., Tang, J., Desai, P., Kopp, E.B., Huang, Y., Song, L., Nakaar, V., and Powell, T.J. (2007). Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25, 763-775. Intlekofer, A.M., Takemoto, N., Kao, C., Banerjee, A., Schambach, F., Northrop, J.K., Shen, H., Wherry, E.J., and Reiner, S.L. (2007). Requirement for T-b<strong>et</strong> in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 204, 2015-2021. Intlekofer, A.M., Takemoto, N., Wherry, E.J., Longworth, S.A., Northrup, J.T., Palanivel, V.R., Mullen, A.C., Gasink, C.R., Kaech, S.M., Miller, J.D., <strong>et</strong> al. (2005). Effector and memory CD8+ T cell fate coupled by T-b<strong>et</strong> and eomeso<strong>de</strong>rmin. Nat Immunol 6, 1236-1244. Isaacs, A., and Lin<strong>de</strong>nmann, J. (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147, 258-267. Iwasaki, A., and Medzhitov, R. (2010). Regulation of adaptive immunity by the innate immune system. Science 327, 291-295. Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Takahara, K., Steinman, R.M., and Inaba, K. (2002). The CD8+ <strong>de</strong>ndritic cell subs<strong>et</strong> selectively endocytoses dying cells in culture and in vivo. J Exp Med 195, 1289-1302. 244
tel-00827710, version 1 - 29 May 2013 Janeway, C.A., Jr. (1989). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1, 1-13. Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G., and Schoenberger, S.P. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852-856. Joffre, O., Nolte, M.A., Sporri, R., and Reis e Sousa, C. (2009). Inflammatory signals in <strong>de</strong>ndritic cell activation and the induction of adaptive immunity. Immunol Rev 227, 234-247. Jongbloed, S.L., Kassianos, A.J., McDonald, K.J., Clark, G.J., Ju, X., Angel, C.E., Chen, C.J., Dunbar, P.R., Wadley, R.B., Je<strong>et</strong>, V., <strong>et</strong> al. (2010). Human CD141+ (BDCA-3)+ <strong>de</strong>ndritic cells (DCs) represent a unique myeloid DC subs<strong>et</strong> that cross-presents necrotic cell antigens. J Exp Med 207, 1247-1260. Joshi, N.S., Cui, W., Chan<strong>de</strong>le, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., and Kaech, S.M. (2007). Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the gra<strong>de</strong>d expression of T-b<strong>et</strong> transcription factor. Immunity 27, 281-295. Jusforgues-Saklani, H., Uhl, M., Blachere, N., Lemaitre, F., Lantz, O., Bousso, P., Braun, D., Moon, J.J., and Albert, M.L. (2008). Antigen persistence is required for <strong>de</strong>ndritic cell licensing and CD8+ T cell cross-priming. J Immunol 181, 3067-3076. Kadowaki, N., Ho, S., Antonenko, S., Malefyt, R.W., Kastelein, R.A., Bazan, F., and Liu, Y.J. (2001). Subs<strong>et</strong>s of human <strong>de</strong>ndritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194, 863-869. Kamphuis, E., Junt, T., Waibler, Z., Forster, R., and Kalinke, U. (2006). Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253-3261. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., <strong>et</strong> al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105. Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11, 373-384. Kla<strong>de</strong>, C.S., Schuller, E., Boehm, T., von Gabain, A., and Manns, M.P. (2012). Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic pepti<strong>de</strong> vaccination. Vaccine 30, 2943-2950. Kleindienst, P., and Brocker, T. (2003). Endogenous <strong>de</strong>ndritic cells are required for amplification of T cell responses induced by <strong>de</strong>ndritic cell vaccines in vivo. J Immunol 170, 2817-2823. Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J., and Murali-Krishna, K. (2005). Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202, 637-650. Kratky, W., Reis e Sousa, C., Oxenius, A., and Sporri, R. (2011). Direct activation of antigenpresenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc Natl Acad Sci U S A 108, 17414-17419. Krebs, P., Barnes, M.J., Lampe, K., Whitley, K., Bahjat, K.S., Beutler, B., Janssen, E., and Hoebe, K. (2009). NK-cell-mediated killing of targ<strong>et</strong> cells triggers robust antigen-specific Tcell-mediated and humoral responses. Blood 113, 6593-6602. Kurts, C., Cannarile, M., Klebba, I., and Brocker, T. (2001). Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol 166, 1439-1442. Page 245 of 256
- Page 1 and 2:
tel-00827710, version 1 - 29 May 20
- Page 3 and 4:
tel-00827710, version 1 - 29 May 20
- Page 5 and 6:
tel-00827710, version 1 - 29 May 20
- Page 7 and 8:
tel-00827710, version 1 - 29 May 20
- Page 9 and 10:
tel-00827710, version 1 - 29 May 20
- Page 11 and 12:
tel-00827710, version 1 - 29 May 20
- Page 13 and 14:
tel-00827710, version 1 - 29 May 20
- Page 15 and 16:
tel-00827710, version 1 - 29 May 20
- Page 17 and 18:
tel-00827710, version 1 - 29 May 20
- Page 19 and 20:
tel-00827710, version 1 - 29 May 20
- Page 21 and 22:
tel-00827710, version 1 - 29 May 20
- Page 23 and 24:
tel-00827710, version 1 - 29 May 20
- Page 25 and 26:
tel-00827710, version 1 - 29 May 20
- Page 27 and 28:
tel-00827710, version 1 - 29 May 20
- Page 29 and 30:
tel-00827710, version 1 - 29 May 20
- Page 31 and 32:
tel-00827710, version 1 - 29 May 20
- Page 33 and 34:
tel-00827710, version 1 - 29 May 20
- Page 35 and 36:
tel-00827710, version 1 - 29 May 20
- Page 37 and 38:
tel-00827710, version 1 - 29 May 20
- Page 39 and 40:
tel-00827710, version 1 - 29 May 20
- Page 41 and 42:
tel-00827710, version 1 - 29 May 20
- Page 43 and 44:
tel-00827710, version 1 - 29 May 20
- Page 45 and 46:
tel-00827710, version 1 - 29 May 20
- Page 47 and 48:
tel-00827710, version 1 - 29 May 20
- Page 49 and 50:
tel-00827710, version 1 - 29 May 20
- Page 51 and 52:
tel-00827710, version 1 - 29 May 20
- Page 53 and 54:
tel-00827710, version 1 - 29 May 20
- Page 55 and 56:
tel-00827710, version 1 - 29 May 20
- Page 57 and 58:
tel-00827710, version 1 - 29 May 20
- Page 59 and 60:
tel-00827710, version 1 - 29 May 20
- Page 61 and 62:
tel-00827710, version 1 - 29 May 20
- Page 63 and 64:
tel-00827710, version 1 - 29 May 20
- Page 65 and 66:
tel-00827710, version 1 - 29 May 20
- Page 67 and 68:
tel-00827710, version 1 - 29 May 20
- Page 69 and 70:
tel-00827710, version 1 - 29 May 20
- Page 71 and 72:
tel-00827710, version 1 - 29 May 20
- Page 73 and 74:
tel-00827710, version 1 - 29 May 20
- Page 75 and 76:
tel-00827710, version 1 - 29 May 20
- Page 77 and 78:
tel-00827710, version 1 - 29 May 20
- Page 79 and 80:
tel-00827710, version 1 - 29 May 20
- Page 81 and 82:
tel-00827710, version 1 - 29 May 20
- Page 83 and 84:
tel-00827710, version 1 - 29 May 20
- Page 85 and 86:
tel-00827710, version 1 - 29 May 20
- Page 87 and 88:
tel-00827710, version 1 - 29 May 20
- Page 89 and 90:
tel-00827710, version 1 - 29 May 20
- Page 91 and 92:
tel-00827710, version 1 - 29 May 20
- Page 93 and 94:
tel-00827710, version 1 - 29 May 20
- Page 95 and 96:
tel-00827710, version 1 - 29 May 20
- Page 97 and 98:
tel-00827710, version 1 - 29 May 20
- Page 99 and 100:
tel-00827710, version 1 - 29 May 20
- Page 101 and 102:
tel-00827710, version 1 - 29 May 20
- Page 103 and 104:
tel-00827710, version 1 - 29 May 20
- Page 105 and 106:
tel-00827710, version 1 - 29 May 20
- Page 107 and 108:
tel-00827710, version 1 - 29 May 20
- Page 109 and 110:
tel-00827710, version 1 - 29 May 20
- Page 111 and 112:
tel-00827710, version 1 - 29 May 20
- Page 113 and 114:
tel-00827710, version 1 - 29 May 20
- Page 115 and 116:
tel-00827710, version 1 - 29 May 20
- Page 117 and 118:
tel-00827710, version 1 - 29 May 20
- Page 119 and 120:
tel-00827710, version 1 - 29 May 20
- Page 121 and 122:
tel-00827710, version 1 - 29 May 20
- Page 123 and 124:
tel-00827710, version 1 - 29 May 20
- Page 125 and 126:
tel-00827710, version 1 - 29 May 20
- Page 127 and 128:
tel-00827710, version 1 - 29 May 20
- Page 129 and 130:
tel-00827710, version 1 - 29 May 20
- Page 131 and 132:
tel-00827710, version 1 - 29 May 20
- Page 133 and 134:
tel-00827710, version 1 - 29 May 20
- Page 135 and 136:
tel-00827710, version 1 - 29 May 20
- Page 137 and 138:
tel-00827710, version 1 - 29 May 20
- Page 139 and 140:
tel-00827710, version 1 - 29 May 20
- Page 141 and 142:
tel-00827710, version 1 - 29 May 20
- Page 143 and 144:
tel-00827710, version 1 - 29 May 20
- Page 145 and 146:
tel-00827710, version 1 - 29 May 20
- Page 147 and 148:
tel-00827710, version 1 - 29 May 20
- Page 149 and 150:
tel-00827710, version 1 - 29 May 20
- Page 151 and 152:
tel-00827710, version 1 - 29 May 20
- Page 153 and 154:
tel-00827710, version 1 - 29 May 20
- Page 155 and 156:
tel-00827710, version 1 - 29 May 20
- Page 157 and 158:
tel-00827710, version 1 - 29 May 20
- Page 159 and 160:
tel-00827710, version 1 - 29 May 20
- Page 161 and 162:
tel-00827710, version 1 - 29 May 20
- Page 163 and 164:
tel-00827710, version 1 - 29 May 20
- Page 165 and 166:
tel-00827710, version 1 - 29 May 20
- Page 167 and 168:
tel-00827710, version 1 - 29 May 20
- Page 169 and 170:
tel-00827710, version 1 - 29 May 20
- Page 171 and 172:
tel-00827710, version 1 - 29 May 20
- Page 173 and 174:
tel-00827710, version 1 - 29 May 20
- Page 175 and 176:
tel-00827710, version 1 - 29 May 20
- Page 177 and 178:
tel-00827710, version 1 - 29 May 20
- Page 179 and 180:
tel-00827710, version 1 - 29 May 20
- Page 181 and 182:
tel-00827710, version 1 - 29 May 20
- Page 183 and 184:
tel-00827710, version 1 - 29 May 20
- Page 185 and 186:
tel-00827710, version 1 - 29 May 20
- Page 187 and 188:
tel-00827710, version 1 - 29 May 20
- Page 189 and 190:
tel-00827710, version 1 - 29 May 20
- Page 191 and 192:
tel-00827710, version 1 - 29 May 20
- Page 193 and 194: tel-00827710, version 1 - 29 May 20
- Page 195 and 196: tel-00827710, version 1 - 29 May 20
- Page 197 and 198: tel-00827710, version 1 - 29 May 20
- Page 199 and 200: tel-00827710, version 1 - 29 May 20
- Page 201 and 202: tel-00827710, version 1 - 29 May 20
- Page 203 and 204: tel-00827710, version 1 - 29 May 20
- Page 205 and 206: tel-00827710, version 1 - 29 May 20
- Page 207 and 208: tel-00827710, version 1 - 29 May 20
- Page 209 and 210: tel-00827710, version 1 - 29 May 20
- Page 211 and 212: tel-00827710, version 1 - 29 May 20
- Page 213 and 214: tel-00827710, version 1 - 29 May 20
- Page 215 and 216: tel-00827710, version 1 - 29 May 20
- Page 217 and 218: tel-00827710, version 1 - 29 May 20
- Page 219 and 220: tel-00827710, version 1 - 29 May 20
- Page 221 and 222: tel-00827710, version 1 - 29 May 20
- Page 223 and 224: tel-00827710, version 1 - 29 May 20
- Page 225 and 226: tel-00827710, version 1 - 29 May 20
- Page 227 and 228: tel-00827710, version 1 - 29 May 20
- Page 229 and 230: tel-00827710, version 1 - 29 May 20
- Page 231 and 232: tel-00827710, version 1 - 29 May 20
- Page 233 and 234: tel-00827710, version 1 - 29 May 20
- Page 235 and 236: tel-00827710, version 1 - 29 May 20
- Page 237 and 238: tel-00827710, version 1 - 29 May 20
- Page 239 and 240: tel-00827710, version 1 - 29 May 20
- Page 241 and 242: tel-00827710, version 1 - 29 May 20
- Page 243: tel-00827710, version 1 - 29 May 20
- Page 247 and 248: tel-00827710, version 1 - 29 May 20
- Page 249 and 250: tel-00827710, version 1 - 29 May 20
- Page 251 and 252: tel-00827710, version 1 - 29 May 20
- Page 253 and 254: tel-00827710, version 1 - 29 May 20
- Page 255 and 256: tel-00827710, version 1 - 29 May 20